NASDAQ:QDEL

QuidelOrtho - QDEL Stock Forecast, Price & News

$71.92

-1.60 (-2.18%)

(As of 10/5/2022 12:00 AM ET)

Add

Compare

Today's Range: $68.94
▼
$72.65
50-Day Range: $69.86
▼
$102.37
52-Week Range: $68.43
▼
$180.06

Volume: 649,948 shs
Average Volume: 725,242 shs
Market Capitalization: $4.82 billion

P/E Ratio: 3.05
Dividend Yield: N/A
Price Target: $96.50

QuidelOrtho MarketRank™ Forecast

Analyst Rating: Hold
2.25 Rating Score
Upside/Downside: 34.2% Upside
$96.50 Price Target
Short Interest: Healthy
4.78% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -2.61
Upright™ Environmental Score
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: -54.57%
From $11.60 to $5.27 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.28 out of 5 stars

Medical Sector

370th out of 1,072 stocks

Diagnostic Substances Industry

8th out of 16 stocks

3.1

Analyst's Opinion

Consensus Rating
QuidelOrtho has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on no buy ratings, 2 hold ratings, and 1 sell rating.
Price Target Upside/Downside
According to analysts' consensus price target of $96.50, QuidelOrtho has a forecasted upside of 34.2% from its current price of $71.92.
Amount of Analyst Coverage
QuidelOrtho has only been the subject of 2 research reports in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
4.78% of the outstanding shares of QuidelOrtho have been sold short.
Short Interest Ratio / Days to Cover
QuidelOrtho has a short interest ratio ("days to cover") of 4.6.
Change versus previous month
Short interest in QuidelOrtho has recently decreased by 5.33%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
QuidelOrtho does not currently pay a dividend.
Dividend Growth
QuidelOrtho does not have a long track record of dividend growth.

3.8

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
QuidelOrtho has received a 49.48% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Sexually transmitted diseases quick tests", "Lactose intolerance quick tests", and "Respiratory tract infection tests" products. See details.
Environmental Sustainability
The Environmental Impact score for QuidelOrtho is -2.61.

1.4

News and Social Media Coverage

News Sentiment
QuidelOrtho has a news sentiment score of 0.57. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.80 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for QuidelOrtho this week, compared to 6 articles on an average week.
Search Interest
Only 11 people have searched for QDEL on MarketBeat in the last 30 days. This is a decrease of -15% compared to the previous 30 days.
MarketBeat Follows
Only 3 people have added QuidelOrtho to their MarketBeat watchlist in the last 30 days. This is a decrease of -40% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, QuidelOrtho insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 2.70% of the stock of QuidelOrtho is held by insiders.
Percentage Held by Institutions
87.20% of the stock of QuidelOrtho is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for QuidelOrtho are expected to decrease by -54.57% in the coming year, from $11.60 to $5.27 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of QuidelOrtho is 3.05, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 125.03.
Price to Earnings Ratio vs. Sector
The P/E ratio of QuidelOrtho is 3.05, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 125.77.
Price to Book Value per Share Ratio
QuidelOrtho has a P/B Ratio of 1.55. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About QuidelOrtho (NASDAQ:QDEL) Stock

QuidelOrtho Corporation focuses on the development and manufacture of diagnostic testing technologies across the continuum of healthcare testing needs. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; and analyzers and amplification systems. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was founded in 1979 and is headquartered in San Diego, California.

Receive QDEL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for QuidelOrtho and its competitors with MarketBeat's FREE daily newsletter.

QDEL Stock News Headlines

September 29, 2022 | reuters.com

QDEL.OQ - Quidelortho Corp | Stock Price & Latest News | Reuters

September 27, 2022 | benzinga.com

Stocks That Hit 52-Week Lows On Tuesday - Universal Insurance Hldgs (NYSE:UVE), Visa (NYSE:V) - Benzinga

September 26, 2022 | benzinga.com

5 Value Stocks To Watch In The Healthcare Sector - Graphite Bio (NASDAQ:GRPH), Baudax Bio (NASDAQ:BXRX), - Benzinga

September 24, 2022 | finance.yahoo.com

QuidelOrtho Corporation (QDEL)

September 23, 2022 | morningstar.com

QuidelOrtho Corp QDEL Stock Quote

September 19, 2022 | nasdaq.com

3 Reasons to Hold QuidelOrtho (QDEL) Stock in Your Portfolio - Nasdaq

September 19, 2022 | seekingalpha.com

QuidelOrtho initiated at neutral at Citi as current valuation is appropriate (QDEL) - Seeking Alpha

September 15, 2022 | benzinga.com

Amazon.com (NASDAQ:AMZN) – Growth stocks: An Overview Into Risk-Heavy Investing - Benzinga

September 14, 2022 | seekingalpha.com

QuidelOrtho Stock: Fundamentals Remain, Upbeat Financials (NASDAQ:QDEL) - Seeking Alpha

September 6, 2022 | businesswire.com

QuidelOrtho to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference - Business Wire

September 6, 2022 | finance.yahoo.com

QuidelOrtho to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference

September 3, 2022 | finance.yahoo.com

QuidelOrtho (NASDAQ:QDEL) shareholders are still up 118% over 5 years despite pulling back 5.8% in the past week - Yahoo Finance

September 3, 2022 | finance.yahoo.com

Quidel and World Champion Los Angeles Rams Partner to Combat COVID-19 and Promote Health Awareness in the L.A. Community - Yahoo Finance

September 2, 2022 | finance.yahoo.com

QuidelOrtho (NASDAQ:QDEL) shareholders are still up 118% over 5 years despite pulling back 5.8% in the past week

September 1, 2022 | businesswire.com

Quidel and World Champion Los Angeles Rams Partner to Combat COVID-19 and Promote Health Awareness in the L.A. Community - Business Wire

September 1, 2022 | finance.yahoo.com

Quidel and World Champion Los Angeles Rams Partner to Combat COVID-19 and Promote Health Awareness in the L.A. Community

August 31, 2022 | nasdaq.com

QuidelOrtho Becomes Oversold (QDEL)

August 30, 2022 | nasdaq.com

Will Weakness in QuidelOrtho Corporation's (NASDAQ:QDEL) Stock Prove Temporary Given Strong Fundamentals? - Nasdaq

August 24, 2022 | globenewswire.com

Helicobacter Pylori Non-invasive Testing Market Revenue to Cross $800.04Mn, Globally, by 2028 to Growing at 4.4% CAGR – Study by The Insight Partners - GlobeNewswire

August 18, 2022 | seekingalpha.com

QuidelOrtho announces $300M share repurchase authorization - Seeking Alpha

August 17, 2022 | businesswire.com

QuidelOrtho Announces $300 Million Share Repurchase Authorization - Business Wire

August 17, 2022 | finance.yahoo.com

QuidelOrtho Announces $300 Million Share Repurchase Authorization

August 16, 2022 | nasdaq.com

Analysts Forecast 13% Gains Ahead For The Holdings of AFMC - Nasdaq

August 12, 2022 | finance.yahoo.com

What You Need To Know About QuidelOrtho Corporation's (NASDAQ:QDEL) Investor Composition

August 11, 2022 | usatoday.com

Want to be sure you don't have COVID? FDA now says you'll need to pass 3 home tests - USA TODAY

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive QDEL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for QuidelOrtho and its competitors with MarketBeat's FREE daily newsletter.

QDEL Company Calendar

Last Earnings: 8/04/2022
Today: 10/05/2022
Next Earnings (Estimated): 11/03/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Diagnostic substances
Sub-Industry: Health Care Supplies
Sector: Medical
Current Symbol: NASDAQ:QDEL
CUSIP: 74838J10
CIK: 353569
Web: www.quidel.com
Phone: (858) 552-1100
Fax: 858-453-4338
Employees: 1,600
Year Founded: 1979

Price Target and Rating

Average Stock Price Forecast: $96.50
High Stock Price Forecast: $130.00
Low Stock Price Forecast: $80.00
Forecasted Upside/Downside: +34.2%
Consensus Rating: Hold
Rating Score (0-4): 2.25
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): $23.60
Trailing P/E Ratio: 3.05
Forward P/E Ratio: 6.20
P/E Growth: N/A
Net Income: $704.23 million
Net Margins: 36.43%
Pretax Margin: 47.80%
Return on Equity: 42.55%
Return on Assets: 28.18%

Debt

Debt-to-Equity Ratio: 0.51
Current Ratio: 1.73
Quick Ratio: 1.12

Sales & Book Value

Annual Sales: $1.70 billion
Price / Sales: 2.83
Cash Flow: $18.78 per share
Price / Cash Flow: 3.83
Book Value: $46.30 per share
Price / Book: 1.55

Miscellaneous

Outstanding Shares: 66,950,000
Free Float: 65,145,000
Market Cap: $4.82 billion
Optionable: Optionable
Beta: 0.18

Social Links

Key Executives

Mr. Douglas C. Bryant (Age 64)
Chairman & CEO
Comp: $1.41M

Mr. Robert J. Bujarski J.D. (Age 53)
Pres & COO
Comp: $770.62k

Ms. Michelle A. Hodges (Age 62)
Gen. Counsel
Comp: $620.61k

Dr. Werner Kroll Ph.D. (Age 65)
Sr. VP of R&D
Comp: $758.22k

Mr. Joseph M. Busky CPA (Age 54)
Chief Financial Officer

Ruben Argueta
Director of Investor Relations

Mr. Michael S. Iskra (Age 52)
Chief Commercial Officer

Phillip S. Askim
VP, Associate Gen. Counsel & Sec.

Dr. Johannes Kehle
Pres of AnDiaTec Division

Mr. Rhys de Callier
VP of Strategy & Portfolio Management

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

QDEL Stock - Frequently Asked Questions

Should I buy or sell QuidelOrtho stock right now?: 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for QuidelOrtho in the last year. There are currently 1 sell rating, 2 hold ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" QDEL shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in QDEL, but not buy additional shares or sell existing shares.
View QDEL analyst ratings or view top-rated stocks.
What is QuidelOrtho's stock price forecast for 2022?: 4 Wall Street research analysts have issued 1-year price objectives for QuidelOrtho's stock. Their QDEL share price forecasts range from $80.00 to $130.00. On average, they anticipate the company's share price to reach $96.50 in the next twelve months. This suggests a possible upside of 34.2% from the stock's current price.
View analysts price targets for QDEL or view top-rated stocks among Wall Street analysts.
How have QDEL shares performed in 2022?: QuidelOrtho's stock was trading at $134.99 at the beginning of 2022. Since then, QDEL stock has decreased by 46.7% and is now trading at $71.92.
View the best growth stocks for 2022 here.
When is QuidelOrtho's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our QDEL earnings forecast.
How were QuidelOrtho's earnings last quarter?: QuidelOrtho Co. (NASDAQ:QDEL) issued its quarterly earnings results on Thursday, August, 4th. The company reported $2.11 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $3.56 by $1.45. The company earned $613.40 million during the quarter, compared to analyst estimates of $572.53 million. QuidelOrtho had a trailing twelve-month return on equity of 42.55% and a net margin of 36.43%.
What guidance has QuidelOrtho issued on next quarter's earnings?: QuidelOrtho updated its FY 2022 earnings guidance on Friday, September, 2nd. The company provided earnings per share guidance of $11.80-$12.75 for the period. The company issued revenue guidance of $3.78 billion-$3.91 billion, compared to the consensus revenue estimate of $2.83 billion.

What is Doug Bryant's approval rating as QuidelOrtho's CEO?: 47 employees have rated QuidelOrtho Chief Executive Officer Doug Bryant on Glassdoor.com. Doug Bryant has an approval rating of 76% among the company's employees.
What other stocks do shareholders of QuidelOrtho own?: Based on aggregate information from My MarketBeat watchlists, some companies that other QuidelOrtho investors own include NVIDIA (NVDA), DocuSign (DOCU), Tesla (TSLA), PayPal (PYPL), Shopify (SHOP), Block (SQ), Teladoc Health (TDOC), Netflix (NFLX), Advanced Micro Devices (AMD) and Zoom Video Communications (ZM).
What is QuidelOrtho's stock symbol?: QuidelOrtho trades on the NASDAQ under the ticker symbol "QDEL."
How do I buy shares of QuidelOrtho?: Shares of QDEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is QuidelOrtho's stock price today?: One share of QDEL stock can currently be purchased for approximately $71.92.
How much money does QuidelOrtho make?: QuidelOrtho (NASDAQ:QDEL) has a market capitalization of $4.82 billion and generates $1.70 billion in revenue each year. The company earns $704.23 million in net income (profit) each year or $23.60 on an earnings per share basis.
How many employees does QuidelOrtho have?: The company employs 1,600 workers across the globe.
How can I contact QuidelOrtho?: QuidelOrtho's mailing address is 9975 SUMMERS RIDGE ROAD, SAN DIEGO CA, 92121. The official website for the company is www.quidel.com. The company can be reached via phone at (858) 552-1100, via email at rargueta@quidel.com, or via fax at 858-453-4338.

This page (NASDAQ:QDEL) was last updated on 10/6/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

QuidelOrtho - QDEL Stock Forecast, Price & News

QuidelOrtho MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows